Human Factors Engineer

Set up as a new job alert
  1. Contract
  2. English
  3. Mid-Senior level
  4. Research & Development
  5. Basel
  6. Healthcare & Life Sciences
  7. Human Factors Engineering, Psychology, product development, risk assesment
This vacancy has now expired
About our client
Our client is one of the leading pharmaceutical companies based in Basel.
On behalf of our client, Swisslinx is seeking a highly motivated individual to take on a challenging contract role in their R&D department.
This is a great opportunity to bring your proven knowledge and expertise to an organization that offers a dynamic working environment.

Your mission:
- Plan, execute, interpret and report formative and summative human factors evaluations, according to current regulations and guidelines within the medical device and pharmaceutical industry
- Define appropriate sample sizes and methods for analysis of human factors activities
- Perform anthropometric, biomechanical, ergonomic, and systems safety analyses to identify and assess risk in product development
- Apply your sound knowledge of the regulatory landscape to ensure standard compliant designs, working to Quality Management Systems, risk management and design control
- Create instructions for use and training material

Your background
- Bachelor degree in Engineering, Psychology, Ergonomics or other relevant studies
- Minimum 4 years of professional experience in a regulated industry
- Experience in design of human factors evaluations
- Experience in medical device or pharmaceutical industry is a strong advantage
- Strong project management skills and efficient and well organized working style
- Fluency in English, with strong technical writing skills, German language knowledge is beneficial

What’s on offer:
Our client offers a unique position with varied responsibilities and gives the opportunity to develop in different areas.
For further information, please do not hesitate to contact Yuliya Olonetzky, Consultant

How has Covid-19 impacted Dubai?


How have startups pivoted to respond to Covid-19?